Home › Funds › Parkman Healthcare Partners LLC › AMLX

Parkman Healthcare Partners LLC position in AMLX

AMYLYX PHARMACEUTICALS INC · Health Care

Parkman Healthcare Partners LLC reported holding 675,101 shares of AMLX (AMYLYX PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$19.6M, representing 1.77% of its reported portfolio and ranking #15 among its reported holdings. Parkman Healthcare Partners LLC has disclosed AMLX holdings in 6 of the last 6 reported quarters, going back to Q2 2025.

Latest position (Q3 2026)675.10K sh
Reported value held$19.65M
Portfolio Weight1.77%
First reportedQ2 2025
Last changeAdd
Updated2026-11-16

Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR

How Parkman Healthcare Partners LLC's AMLX position evolved

Parkman Healthcare Partners LLC first disclosed a stake in AMLX in Q2 2025 at 650,000 shares (US$4.2M). The position peaked in Q3 2026 at 675,101 shares, worth US$19.6M. Across 6 filings, Parkman Healthcare Partners LLC increased the stake 2 time(s), trimmed it 3 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 675,101 shares valued at US$19.6M — an increase of 276,319 shares quarter over quarter.. Notable position changes include a 63% increase in Q1 2026 (shares rose 29% over the following quarter), a 36% trim in Q2 2026 (shares rose 62% over the following quarter), a 69% increase in Q3 2026 (shares rose 4% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q2 2025 650.00K $4.17M New
Q3 2025 579.17K $7.87M Reduce
Q4 2025 381.76K $4.61M Reduce
Q1 2026 621.46K $8.64M Add
Q2 2026 398.78K $7.16M Reduce
Q3 2026 675.10K $19.65M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About AMLX and 13F data

AMLX (AMYLYX PHARMACEUTICALS INC) is a Health Care company. 46 other funds we track also report a position in AMLX — the largest reported positions include TCG Crossover Management, LLC (US$181.7M), DRIEHAUS CAPITAL MANAGEMENT LLC (US$158.0M), PERCEPTIVE ADVISORS LLC (US$149.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding AMLX

All AMLX fund holders →

FAQ

How long has Parkman Healthcare Partners LLC held AMLX?

Parkman Healthcare Partners LLC has disclosed AMLX holdings in 6 of the last 6 reported quarters, going back to Q2 2025.

What is Parkman Healthcare Partners LLC's current position in AMLX?

As of Q3 2026, Parkman Healthcare Partners LLC holds 675.10K shares of AMLX (AMYLYX PHARMACEUTICALS INC), valued at $19.65M, representing 1.77% of its reported portfolio and ranking #15.

Has Parkman Healthcare Partners LLC been buying or selling AMLX?

In the latest 13F filing (Q3 2026), Parkman Healthcare Partners LLC increased its position in AMLX. The position peaked in Q3 2026 at 675.10K shares.

Which other funds hold AMLX?

Other major institutional holders of AMLX include TCG Crossover Management, LLC, DRIEHAUS CAPITAL MANAGEMENT LLC, PERCEPTIVE ADVISORS LLC, among 46 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.